Acetazolamide and Sabril drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Acetazolamide (acetazolamide) and Sabril (vigabatrin). Common drug interactions include hypersomnia among females and drug withdrawal convulsions among males.

The phase IV clinical study analyzes what interactions people have when they take Acetazolamide and Sabril. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Acetazolamide?

Acetazolamide has active ingredients of acetazolamide. It is often used in pseudotumor cerebri. eHealthMe is studying from 6,178 Acetazolamide users. Check the latest studies of Acetazolamide.

What is Sabril?

Sabril has active ingredients of vigabatrin. eHealthMe is studying from 12,445 Sabril users. Check the latest studies of Sabril.



On Jul, 12, 2026

17 people who take Acetazolamide and Sabril together, and have interactions are studied.

Acetazolamide and Sabril drug interactions.

What are the common drug interactions of Acetazolamide and Sabril, by gender? *:

female:

  1. Hypersomnia (excessive daytime sleepiness (eds))
  2. Dizziness
  3. Head discomfort
  4. Hyperhidrosis (abnormally increased sweating)
  5. Palpitations (feelings or sensations that your heart is pounding or racing)
  6. Pneumonia
  7. Seasonal allergy (allergic condition due to certain season)
  8. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  9. Abdominal discomfort
  10. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)

male:

  1. Drug withdrawal convulsions
  2. Eye disorder
  3. Optic neuropathy (optic nerve damage)
  4. Retinal toxicity (retina damage due to medication)
  5. Cardiac arrest
  6. Diarrhoea
  7. Multiple injuries
  8. Road traffic accident
  9. Staphylococcal infection (an infection with staphylococcus bacteria)

What are the common drug interactions of Acetazolamide and Sabril, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Hypersomnia (excessive daytime sleepiness (eds))
  2. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  3. Abdominal discomfort
  4. Diarrhoea
  5. Nausea (feeling of having an urge to vomit)
  6. Adverse drug reaction
  7. Cardiac arrest
  8. Hypophagia (reduced food intake)

20-29:

  1. Essential tremor
  2. Nephrolithiasis (calculi in the kidneys)

30-39:

  1. Optic neuropathy (optic nerve damage)
  2. Retinal toxicity (retina damage due to medication)
  3. Drug withdrawal convulsions
  4. Eye disorder

40-49:

n/a

50-59:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  3. Hypersensitivity
  4. Therapeutic response decreased (less preventive response)
  5. Diarrhoea
  6. Multiple injuries
  7. Road traffic accident
  8. Staphylococcal infection (an infection with staphylococcus bacteria)

60+:

n/a

What are the existing conditions these people have? *

  1. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 10 people, 58.82%
  2. Cerebral Palsy: 3 people, 17.65%
  3. Complex Partial Seizures (epileptic seizure): 3 people, 17.65%
  4. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 17.65%
  5. Partial Seizures (seizures which affect only a part of the brain at onset): 3 people, 17.65%
  6. Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 2 people, 11.76%
  7. Constipation: 2 people, 11.76%
  8. Diarrhea: 2 people, 11.76%
  9. Drooling (drop saliva uncontrollably from the mouth): 2 people, 11.76%
  10. Facial Spasm (involuntary muscle contractions face): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Acetazolamide and Sabril?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Acetazolamide and Sabril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Acetazolamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Sabril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Acetazolamide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sabril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on acetazolamide and vigabatrin (the active ingredients of Acetazolamide and Sabril, respectively), and Acetazolamide and Sabril (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: